Adverse effects of inhaled corticosteroids

NA Hanania, KR Chapman, S Kesten - The American journal of medicine, 1995 - Elsevier
Inhaled corticosteroids are considered by many to be the anti-inflammatory therapy of choice
in adult asthma, given their remarkable efficacy and apparent safety. They are presently …

[HTML][HTML] A 4-year trial of tiotropium in chronic obstructive pulmonary disease

…, B Celli, S Senn, D Burkhart, S Kesten… - … England Journal of …, 2008 - Mass Medical Soc
Background Previous studies showing that tiotropium improves multiple end points in
patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term …

Bronchiolitis obliterans after lung transplantation: a review

A Boehler, S Kesten, W Weder, R Speich - Chest, 1998 - journal.chestnet.org
A sa result of improvements in surgical techniques, immunosuppression, and postoperative
management, the current 1-year survival rate following lung transplantation is 71%, and 46% …

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

…, APM Greefhorst, TA Bantje, S Kesten… - European …, 2002 - Eur Respiratory Soc
Tiotropium, a novel once-daily inhaled anticholinergic, has been shown to improve lung
function over a 24-h period. In order to extend these findings, health-outcomes were evaluated …

Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

…, M Miravitlles, L Korducki, L Towse, S Kesten - Thorax, 2006 - thorax.bmj.com
Background: A study was undertaken to record exacerbations and health resource use in
patients with COPD during 6 months of treatment with tiotropium, salmeterol, or matching …

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

…, ED Bateman, SJ Langley, A Lee, TJ Witek Jr, S Kesten… - Chest, 2002 - Elsevier
Background Tiotropium, a once-daily anticholinergic, and salmeterol represent two inhaled,
long-acting bronchodilators from different pharmacologic classes. A trial was designed to …

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised …

M Decramer, B Celli, S Kesten, T Lystig, S Mehra… - The Lancet, 2009 - thelancet.com
… Primary endpoints were the yearly rates of decline in prebronchodilator forced expiratory
volume in 1 s (FEV 1 ) and in postbronchodilator FEV 1 , beginning on day 30 until completion …

Bronchodilator responsiveness in patients with COPD

…, D Liu, D Burkhart, C Cassino, S Kesten - European …, 2008 - Eur Respiratory Soc
… supplemental oxygen for >12 h·day −1 or had a significant disease other than COPD that,
in the opinion of the investigator, might influence either the results of the study or the patient’s

Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes

B Celli, R ZuWallack, S Wang, S Kesten - Chest, 2003 - Elsevier
… for evaluating the severity of the airflow obstruction and monitoring the progression of
disease, these assessments do not adequately profile the full impact of COPD on the patient’s

Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD

…, D Kukafka, CB Cooper, TJ Witek Jr, S Kesten - Chest, 2005 - Elsevier
… B Cooper MD, FCCP c , Theodore J Witek Jr DrPH d , Steven Kesten MD, FCCP d …
Witek and Kesten areemployees of Boehringer-Ingelheim Pharmaceuticals. This study was …